循環器系

As your cardiovascular CRO, we deliver rapid study start up timelines, on time deliverables, proactive risk management and quality data, achieving study timelines within projected budgets. We understand that small biotech companies need a partner who can complement their limited staff and be sensitive to budget restrictions.

We are experienced in working with smaller biotech companies in a variety of models and can easily adapt to your needs. Our individual cardiovascular group provides a small CRO feel with all the benefits of being a large CRO.

We understand the nuances of successfully running a global, cardiovascular outcomes trial (CVOT). That’s why we have staff in medical leadership, project management, clinical operations, pharmacovigilance and statistics with CVOT experience who can execute trials using proven effective strategies.

循環器系治験に関するサイネオス・ヘルスの実績

We have extensive experience in cardiovascular clinical trials and research, including new therapies such as stem cells, HFpEF, HFrEF, SGLT-2 inhibitors and large, global CVOTs. Our experts have created strategy plans that expedite timelines and deliver superb data quality while adhering tightly to sponsors’ budgets. We have worked on indications for cardiovascular drugs in the following areas:

• 急性冠症候群
• 狭心症
• 不整脈
• 心臓血管外科
• 深部静脈血栓症
• 糖尿病
• 脂質異常症
• 心不全
• 高血圧
• 脂質異常症
• 虚血性心疾患
• 肥満
• 末梢動脈障害
• 肺高血圧
• 腎不全（急性および慢性）
• 静脈血栓塞栓症（VTE）

高品質の循環器系臨床データを、グローバルでの一貫性を保ち、安全に取得します。

Our web-based electronic endpoint adjudication system is specially tailored for long-term, large-scale, global cardiovascular clinical trials and research. We use it together with our innovative data monitoring strategies, which employ risk-based techniques encouraged by regulatory authorities to improve patient safety while providing cost efficiencies.